These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 16199312

  • 1. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
    Berthelet E, Pickles T, Lee KW, Liu M, Truong PT, Prostate Cancer Outcomes Initiative.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):781-7. PubMed ID: 16199312
    [Abstract] [Full Text] [Related]

  • 2. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 3. What is the optimal duration of androgen deprivation therapy in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/ml?
    Berthelet E, Pickles T, Truong PT, Liu M, Pai HH, Kwan WB, Lim JT, Members of the Prostrate Cancer Outcomes Initiative.
    Can J Urol; 2007 Aug 15; 14(4):3621-7. PubMed ID: 17784982
    [Abstract] [Full Text] [Related]

  • 4. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1322-31. PubMed ID: 16029788
    [Abstract] [Full Text] [Related]

  • 5. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 6. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR, Presti JC, Gill H, Brooks J, Hancock SL.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):341-7. PubMed ID: 15145146
    [Abstract] [Full Text] [Related]

  • 7. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug 01; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

  • 15. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C, Martínez A, Galalae R, Demanes J, Harsolia A, Schour L, Nuernberg N, Gonzalez J.
    Prostate Cancer Prostatic Dis; 2006 Aug 01; 9(3):245-53. PubMed ID: 16786040
    [Abstract] [Full Text] [Related]

  • 16. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
    Akimoto T, Kitamoto Y, Saito J, Harashima K, Nakano T, Ito K, Yamamoto T, Kurokawa K, Yamanaka H, Takahashi M, Mitsuhashi N, Niibe H.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):372-9. PubMed ID: 15145150
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer.
    Zelefsky MJ, Ben-Porat L, Chan HM, Fearn PA, Venkatraman ES.
    Int J Radiat Oncol Biol Phys; 2006 Oct 01; 66(2):382-8. PubMed ID: 16965990
    [Abstract] [Full Text] [Related]

  • 20. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD.
    Urology; 2007 Mar 01; 69(3):541-6. PubMed ID: 17382161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.